ANI Pharmaceuticals
ANIP
126 hedge funds and large institutions have $391M invested in ANI Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 18 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 33
32% more call options, than puts
Call options by funds: $905K | Put options by funds: $688K
18% more capital invested
Capital invested by funds: $330M → $391M (+$61M)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding
Funds holding: 126 → 126 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.18% less ownership
Funds ownership: 58.92% → 58.74% (-0.18%)
Top Buyers
Top Sellers
ANIP Hedge Fund Activity: Q4 2022 in Review
126 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2022, worth a combined $391M — up 18% from $330M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ANIP positions and 18 closed out — a net gain of 1 holder — while 46 added to existing stakes and 33 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $3.35M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $4.47M sold.
- 126 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $391M of ANI Pharmaceuticals stock for Q4 2022, up 18% quarter-over-quarter.
- 19 funds opened new ANI Pharmaceuticals positions in Q4 2022 and 18 closed out, a net change of +1 holder.
- The largest ANI Pharmaceuticals buyer in Q4 2022 was Rubric Capital Management (New York), an estimated $3.35M added.
- The largest ANI Pharmaceuticals seller in Q4 2022 was Balyasny Asset Management, an estimated $4.47M sold.
Based on aggregated 13F filings for Q4 2022.